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Efficient immune responses to HIV-1 gene products are essential elements to the development and design of an effective vaccine. Ideally,
both humoral and cellular responses will be optimally elicited. It is therefore important to elucidate any factors that might limit the
immunogenicity of HIV-1 proteins that are likely to be included in an effective vaccine. Since the HIV-1 exterior envelope glycoprotein
gp120 is a major target for neutralizing antibodies, it is a virtual certainty that this gene product will be a component of any vaccine that seeks
to elicit neutralizing antibody responses from the host humoral immune system. We report here the testing of several HIV-1 gp120 variants
derived from a primary isolate that appears deficient in eliciting immune responses at both the level of CD4+ help and consequently in the
generation of high-affinity IgG antibody responses in small animals. Factors limiting an effective immune response include (a) envelope
glycoprotein strain variation decreasing functional T-cell help, (b) alteration of the glycosylation patterns of gp120 by expression in different
cell types, and (c) the native structure of gp120 itself, which may limit the elicitation of effective T-cell help during natural infection or during
parenteral immunization in adjuvant. Such limiting factors and others should be considered in the design and testing of gp120-based
immunogens in small animals and possibly in primates as well.
Published by Elsevier Inc.
Keywords: HIV-1; Envelope glycoproteins; ImmunogenicityIntroduction
The HIV-1 envelope glycoproteins facilitate binding of
the virus to target cells and mediate fusion and entry (Wyatt
and Sodroski, 1998). The envelope glycoproteins are the
major targets for neutralizing antibodies in vivo and are the
principal component in the design of subunit vaccines. The
HIV-1 exterior envelope glycoprotein gp120 binds sequen-
tially to the primary viral receptor CD4 and the coreceptors0042-6822/$ - see front matter. Published by Elsevier Inc.
doi:10.1016/j.virol.2004.08.037
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The transmembrane glycoprotein gp41 then mediates the
fusion process (Kowalski et al., 1987; Wyatt and Sodroski,
1998). The gp120 and gp41 envelope glycoproteins form a
noncovalently linked heterotrimeric spike on the surface of
the virus and on infected cells (Earl et al., 1991).
A neutralizing antibody response is likely to be a critical
component of an effective HIV-1 vaccine. The titers of
neutralizing antibodies have been found to correlate with the
degree of protection from viral challenge in several animal
models (Berman et al., 1990; Bruck et al., 1994).
Furthermore, in passive transfer studies, broadly neutraliz-
ing monoclonal antibodies have been shown to protect from
viral challenge when administered to the host prior to04) 233–248
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1999; Parren et al., 2001). However, broadly neutralizing
antibodies, especially against primary isolates, have proven
to be exceptionally difficult to elicit in vaccinated animals or
individuals using Env-based immunogens.
The gp120 glycoprotein is comprised of constant
regions (C1–C5) and variable regions (V1–V5) with four
of the variable regions being cysteine linked at each base
(Starcich et al., 1986). Whereas the variable loop V3
contributes to coreceptor binding (Rizzuto and Sodroski,
2000; Rizzuto et al., 1998; Wu et al., 1996), the V1–V2
loops are dispensable for viral infection of target cells
(Kolchinsky et al., 2001; Wyatt et al., 1993, 1995). The
five constant regions are functionally indispensable as
they constitute the core molecule and contribute most of
the interactions with CD4, coreceptors, and gp41 (Kwong
et al., 1998). The variable loops present a myriad of
different epitopes to the immune system and therefore
many of the protein determinants contained in the variable
loops serve as bdecoyQ targets, directing the antibody
response away from the functionally conserved regions of
gp120. The variable loops also shield neutralization-
sensitive surfaces, such as the conserved receptor binding
regions, from antibodies by steric blockade (Wyatt and
Sodroski, 1998). Therefore, deletion of the variable loops
V1, V2, or V3 has been suggested as a means to generate
envelope glycoprotein-based immunogens that preferen-
tially elicit antibodies against conserved regions of gp120
such as the CD4 binding site (Barnett et al., 2001; Wyatt
et al., 1993).
CD4+ helper T-cells are the major target for HIV-1
infection and play a key role in the immune response to
viral infection. The loss of specific anti-HIV-1 CD4+
helper T-cells has been suggested to be important for the
failure of host immune responses (Douek et al., 2002;
Rosenberg et al., 1997). Most large proteins possess one or
more contiguous stretches of amino acids that can function
as CD4+ T-cell helper epitopes (Rudensky et al., 1991).
Sequence comparison of helper epitopes naturally pre-
sented by the major histocompatibility complex (MHC)
class II and structural analysis of MHC and MHC–peptide
complexes suggest that key anchor residues are necessary
for MHC class II binding and T-cell receptor (TCR)
engagement (Brown et al., 1993; Hunt et al., 1992;
Rudensky et al., 1991, 1992). Although each MHC allele
is characterized by a number of unique polymorphic
residues along the peptide-binding cleft that limits the
number of potential peptide ligands, peptides that are able
to bind promiscuously to a number of different MHC
alleles have been described (Ceppellini et al., 1989;
Panina-Bordignon et al., 1989; Sinigaglia et al., 1988).
This observation gave rise to the concept of buniversal
helper-epitopesQ, peptides that can serve as T-helper
epitopes for a number of different MHC class II alleles.
One such universal T-helper epitope has been termed pan-
DR-helper epitope (PADRE; Epimmune) (Alexander et al.,1994). This peptide was shown to bind 10 out of 10 tested
HLA-DR molecules and was also shown to bind to certain
mouse MHC class II alleles.
We created gp120 molecules deleted of the V1 and V2
variable loops to remove potential steric barriers to the
conserved receptor binding sites and to limit the number
of variable determinants presented to the immune system.
The V3 loop was retained because conserved elements of
V3 may be involved in coreceptor binding (Wu et al.,
1996). We also deleted the N- and C-termini of gp120 to
remove immunodominant non-neutralizing determinants
(see Fig. 1S, Supplementary Information). Here, we show
that these core+V3 gp120 envelope glycoproteins from the
primary HIV-1 isolate YU2, when expressed in insect cells,
are deficient in eliciting functional T-cell help in two small
animal models. By functional help, we mean efficient
generation of a T-cell-dependent IgG antibody response.
This deficiency was less pronounced for envelope proteins
derived from the T cell line-adapted (TCLA) isolate HXBc2.
In addition to gp120 core+V3 envelope glycoproteins, we
show that full-length gp120 glycoproteins derived from the
primary isolate YU2, when expressed in insect cells, are
also deficient in eliciting antibody responses in immunized
animals. This deficiency of both core+V3 and full-length
gp120 can be overcome by the addition of heterologous T-
helper epitopes or, for full-length gp120, by expression in
mammalian cells or denaturation of the proteins. These data
indicate that the elicitation of functional T-cell-dependent
help by native gp120 glycoproteins is suboptimal in these
test systems and may be influenced by several factors. That
gp120 has limited functional T-cell help when expressed in
small animals or in rhesus macaques has been previously
observed (Sarkar et al., 2002a, 2002b; Surman et al., 2001;
Zhan et al., 2003). These observations have implications for
subunit vaccine design, production, and testing based upon
gp120 variants, which are still undergoing modification and
analysis as subunit vaccine candidates in small animal test
systems (Buge et al., 2003; Liao et al., 2002; Pantophlet et
al., 2003) and may be relevant for optimal responses to
immunogens in nonhuman and human primates.Results
Anti-gp120 IgG reactivity in mouse sera raised against
YU2 core+V3 gp120 and HXBc2 core+V3 gp120
glycoproteins with and without heterologous T-cell
helper epitopes
The gp120 core+V3 envelope glycoproteins (D82DV1/
V2D492) were initially designed to elicit virus-neutralizing
antibodies against conserved elements maintained in the
gp120 core+V3. Preliminary data in Balb/c mice indicated
that the YU2 core+V3 gp120 did not elicit an IgG response
whereas the HX core+V3 was immunogenic, suggesting
that in the YU2 core+V3 glycoproteins were immunodefi-
C. Grundner et al. / Virology 330 (2004) 233–248 235cient and might lack functional T help. To test if the
absence of serum IgG reactivity against core+V3 gp120
derived from the primary isolate YU2 was due to a lack of
functional T-helper epitopes in this protein, both HXBc2
and YU2 core+V3 gp120 molecules were expressed as
fusion proteins with the heterologous helper epitope
PADRE appended on both the N- and C-termini. PADRE
sequences had been previously shown to bind to class II
molecules expressed by C57/BL6 mice, allowing us to
investigate the suboptimal immunogenicity in another
mouse strain. The gp120 core glycoproteins containing
the heterologous T-helper epitope (TH) sequences at both
their N- and C-termini were designated core+V3-TH. To
confirm the presence of the TH sequences on the core+V3
gp120, the proteins were subjected to 12% SDS-PAGE
analysis (Fig. 1A, inset). A difference in electrophoretic
mobility between the core+V3 gp120 and the core+V3-TH
gp120 could be detected. This difference in mobilityFig. 1. (Panel A) ELISA of anti-gp120 IgG reactivity of mouse sera raised against
(right panel). Mice were inoculated four times with core+V3 gp120 and core+V
HXBc2 core+V3 gp120 and YU2 core+V3 gp120 antigens, respectively. The da
Coomassie-stained 12% SDS-PAGE of Drosophila-expressed core+V3 gp120 (lan
respectively. The core+V3-TH gp120 proteins (lanes 2 and 4) migrate slightly slo
gp120 IgG reactivity in pooled sera from five mice raised against YU2 gp120 (clo
squares), detected by ELISA after the second (circles) and the third inoculations (sq
signal.corresponds to the difference expected for the core+V3
gp120 proteins and the fusion proteins carrying two repeats
of TH sequences with an additional molecular weight of
approximately 2.6 kDa.
To then test if the addition of heterologous helper
epitopes could restore the immunogenicity of the primary
isolate-derived core+V3 gp120, YU2 core+V3 gp120 and
core+V3-TH gp120 were inoculated into groups of five
C57BL/6 mice. C57BL/6 mice express the MHC class II
I-Ab allele that has been shown to bind the TH epitope
with high affinity (Alexander et al., 1994). HXBc2
core+V3 gp120 and HXBc2 core+V3-TH gp120 were
inoculated in parallel. After three inoculations, sera from
individual mice immunized with the YU2 and HX
core+V3 glycoproteins (without the TH epitopes) were
tested for serum IgG reactivity to homologous core+V3
gp120 glycoproteins (Table 1). As was seen in our
preliminary experiments, the HXBc2 core+V3 gp120core+V3 gp120 and core+V3-TH gp120 from HXBc2 (left panel) and YU2
3-TH gp120 from HXBc2 or YU2 immunogens. Sera were tested against
ta were generated from pooled serum of five individual animals. (Insets)
es 1 and 3) and core+V3-TH gp120 (lanes 2 and 4) from HXBc2 and YU2,
wer due to the additional N- and C-terminal TH sequences. (Panel B) Anti-
sed circles and squares) and YU2 gp120-TH immunogens (open circles and
uares) in Ribi adjuvant. Preimmune sera (open triangles) gave no detectable
Table 1
Average and standard deviation ELISA values from individual sera (five per group) post 3rd inoculation
Immunogens Reciprocal dilution
100 500 2500 12, 500 62, 500 312, 500
HX core+V3 3.64 F 0.05 3.68 F 0.06 3.69 F 0.19 2.91 F 0.95 1.69 F 1.23 0.66 F 0.54
YU2 core+V3 0.14 F 0.04 0.03 F 0.02 0.03 F 0.01 0.01 F 0.01 0.00 F 0.01 0.00 F 0.02
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glycoproteins elicited an extremely poor IgG response to
gp120. The responses shown in Table 1 were highly
consistent within each group with relatively small standard
deviations. Observing such consistent responses, we then
chose to analyze serum pools for most subsequent mouse
bleeds and experiments.
Following four inoculations, the sera from all groups of
mice were pooled and IgG titers directed against the
HXBc2 or YU2 core+V3 proteins were determined by
ELISA. Pooled, prebleed sera were treated similarly (Fig.
1A). The titers raised against the HXBc2 core+V3 gp120
and core+V3-TH gp120 were similar, with endpoint titers
of greater than 100,000 (Fig. 1A, left panel). Thus, there
was no obvious effect of the TH epitope on the
immunogenicity of HXBc2 core+V3 gp120 after four
inoculations, although after two inoculations there was a
benefit of adding heterologous helper epitopes to this
protein (Fig. 2S, Supplementary Information). The titers
raised against YU2 core+V3 protein by immunization with
the YU2 core+V3-TH gp120, in contrast, were markedly
higher than the titers raised by immunization with the YU2
core+V3 gp120 (Fig. 1A, right panel). The sera of animals
immunized with YU2 core+V3-TH gp120 exhibited end-
point titers of greater than 100,000 against the YU2
core+V3 protein. These titers were similar to those observed
for the immune and preimmune sera of the animals
inoculated with HXBc2 core+V3 gp120, whereas the YU2
core+V3 gp120 did not elicit any detectable antibody
response against the homologous protein. These data
demonstrate that the addition of the heterologous helper
epitope TH fully restored the immunogenic potential of the
YU2 core+V3 gp120.
Serum reactivity against TH or neoepitopes
To rule out the possibility that the increase in anti-gp120
serum reactivity observed in sera raised against YU2
core+V3-TH gp120 compared to YU2 core+V3 gp120
was due to reactivity of these sera against the TH epitope
itself, or neo-epitopes created by the fusion of TH with the
core+V3 gp120, serum raised against YU2 core+V3-TH
gp120 was tested by ELISA for reactivity to YU2 core+V3
gp120 and YU2 core+V3-TH gp120 antigen. The reactivity
of serum raised against YU2 core+V3-TH gp120 to YU2
core+V3 gp120 antigen was approximately equivalent to the
reactivity to the YU2 core+V3-TH gp120 antigen (Fig. 3S,
Supplementary Information).Anti-gp120 IgG and IgM responses elicited by core+V3
gp120 and core+V3-TH gp120 in rabbits
A strong deficiency of the core+V3 gp120 of the
primary isolate YU2 to elicit anti-gp120 IgG in two strains
of mice was observed. This lack of an IgG response could
be restored by the addition of heterologous T-helper
epitopes. Both strains of mice, however, possess a very
limited number of MHC II alleles; I-Ab in the C57BL/6
mice and I-Ad and I-Ed in the BALB/c mice. To exclude
the possibility that the observed deficiency in functional T-
helper epitopes of the primary isolate YU2 core+V3 gp120
is an effect only manifest in the context of a limited MHC
class II heterogeneity, the YU2 core+V3 gp120 and YU2
core+V3-TH gp120s were inoculated into outbred rabbits.
Groups of five New Zealand White rabbits were inoculated
with 20 Ag of gp120 and serum was collected after each
inoculation following the priming. The pooled sera were
tested for anti-gp120 IgG reactivity by ELISA. Generally,
the same poor elicitation of an anti-gp120 antibody
response by the YU2 core+V3 gp120 was observed as
before in mice (Fig. 2). The serum raised against YU2
core+V3-TH gp120 showed consistently higher anti-gp120
reactivity than did the YU2 core+V3 gp120 serum. The
YU2 core+V3 gp120, however, did elicit slightly higher
antibody titers in rabbits compared to mice, perhaps
indicating that the helper epitope deficiency was less
pronounced in this particular MHC class II context. The
difference between the antibody titers raised against YU2
core+V3 gp120 and YU2 core+V3-TH gp120 diminished
slightly from the third inoculation to the fourth inoculation
(Fig. 2). When endpoint titers of the respective animals
were determined after the third and fourth inoculations,
sera raised against YU2 core+V3-TH gp120 displayed
endpoint titers of approximately 12,500 compared to
endpoint titers raised with the YU2 core+V3 gp120 of
2500 (Fig. 2). Analysis of individual sera from the YU2
core+V3 group revealed that only one rabbit (#54) had a
high titer anti-gp120 response equivalent to the responses
in the core+V3-TH group. When data from the responder
animal #54 were analyzed separately from the remainder
of the core+V3 gp120 group, the difference between the
two groups became more pronounced (Fig. 2). After
inoculation three, the endpoint titer for the core+V3-TH
gp120 group was approximately 12,500, whereas the
endpoint titers in the core+V3 gp120 group were
approximately 2500 with, and about 5-fold lower without,
the responder animal #54. The fact that the #54 rabbit
Fig. 2. ELISA of IgG reactivity against YU2 gp120 in rabbit sera. Serum was collected after two, three, and four inoculations with YU2 core+V3 gp120 and
YU2 core+V3-TH gp120 immunogens, respectively, and anti-gp120 reactivity was tested against YU2 gp120 antigens. The anti-YU2 gp120 IgG reactivity
from pooled serum of five rabbits inoculated with YU2 core+V3 gp120, the responder animal #54 from the group inoculated with YU2 core+V3 gp120 is
plotted separately, and core+V3-TH gp120 is shown.
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similar to the rabbits immunized with YU2 core+V3-TH
gp120 indicates that the pronounced differences observed
for the other animals in the core+V3 gp120 group and
core+V3-TH gp120 group are likely due to individual
animal variation because of MHC heterogeneity or other
differences and not merely due to variance in the dose of
the inocula.
To assess the anti-gp120 IgM reactivity in sera raised
against the core+V3 gp120, serum of rabbits inoculated with
YU2 core+V3 gp120 and YU2 core+V3-TH gp120s was
tested by ELISA. Generally, similar low titers of anti-gp120
IgM could be detected in all animals (not shown).
Anti-gp120 IgG reactivity in mouse sera raised against YU2
full-length gp120 and gp120-TH and ELISPOT data are
consistent with a TH2 immune response
To explore the immunogenic properties of full-length
gp120 derived from the primary isolate YU2 and to test the
immunogenic effect of TH sequences in this context, full-
length, wild-type (WT) gp120 and gp120-TH envelopeglycoproteins were produced in insect cells, purified, and
inoculated into groups of five C57BL/6 mice. After two and
three inoculations, sera were tested for anti-gp120 IgG
reactivity by ELISA. As previously observed with YU2
core+V3 gp120, YU2 WTgp120 elicited low titers of anti-
gp120 antibodies. Sera from the group inoculated with the
WTgp120-TH, in contrast, elicited much higher titers of
anti-gp120 IgG (Fig. 1B). A boosting effect was apparent
after the third inoculation, with WTgp120-TH eliciting
titers approximately 5-fold higher than those observed after
the second inoculation.
To determine the subclass composition of the IgG
response in these mice, anti-gp120 sera were analyzed with
subclass-specific secondary antibodies by ELISA (Fig. 3A).
The sera raised against the soluble, WTgp120-TH protein in
Ribi adjuvant predominantly consisted of antibodies of the
IgG1 subclass. Only very low levels of antibodies of the IgG2a
subclass could be detected, consistent with WTgp120-TH
protein eliciting a predominant, T-cell dependent TH2
immune response.
To support the conclusion that the response of the YU2
WTgp120-TH mice was a TH2-dependent immune response,
Fig. 3. (Panel A) Subclass composition of sera raised against gp120 and gp120-TH immunogens in mice. Anti-gp120 sera were tested for the presence of IgG1
and IgG2a subclass antibodies by subclass-specific secondary antibodies (left panel). Data for the positive control IgG proteins are shown in the right hand
panel. Values shown are from one representative ELISA of two independent experiments. The error bars indicate the range of values obtained for duplicate
samples. (Panel B) IL-4 ELISPOT results of three mice from the group inoculated with Drosophila YU2 gp120 in Ribi adjuvant and two mice from the group
immunized with YU2 WTgp120-TH proteins. Splenocytes from all mice were stimulated with 0.1 and 1 Ag of WTgp120-TH protein and the IL-4 production is
shown as the average of two duplicate wells and error bars represent the range of values obtained for duplicate samples.
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can be seen in Fig. 3B, the two mice examined from the
WTgp120-TH group demonstrated IL-4 ELISPOT responses
that were significantly greater than those observed in animals
inoculated with WTgp120 protein.
Carbohydrate reactivity in sera raised against core+V3
gp120, core+V3 gp120-TH, full-length WTgp120, and
WTgp120-TH in mice and rabbits
Heterologous helper epitopes are capable of breaking
natural immunologic tolerance against self-determinants
(Dalum et al., 1997). The gp120 envelope glycoprotein is
heavily glycosylated with about half of its molecular weight
being contributed by host carbohydrate that is likely
considered bselfQ by the human immune system. Breaking
tolerance to these glycans may generate a substantial anti-
carbohydrate antibody response that would represent a trivial
explanation for the effects of the heterologous helper epitope
observed here. Therefore, we tested the possibility that the
addition of TH sequences to the gp120 glycoproteinsincreases the generation of carbohydrate-directed antibodies
in either mice or rabbits.
Sera elicited in mice against HXBc2 core+V3 gp120,
HXBc2 core+V3-TH gp120, and YU2 core+V3-TH gp120
were tested for IgG reactivity against wild-type (WT) gp120
and enzymatically deglycosylated, strain-matched gp120 by
ELISA. Sera elicited by YU2 WTgp120-TH in mice were
subjected to the same analysis and in each case no significant
loss of reactivity to the deglycosylated gp120 was observed.
The endpoint titers obtained against WT, glycosylated, and
deglycosylated gp120 antigens were similar (Fig. 4A, left
panel and not shown). The high titer serum raised in mice
against mammalian-made YU2 WTgp120 also did not
display detectable anti-carbohydrate reactivity as determined
by these methods (Fig. 4A, right panel).
Because the insect-produced proteins append high-
mannose glycans and lack complex carbohydrate modifica-
tions, any elicited glycan-specific antibodies should be
directed against high-mannose epitopes. Therefore, a second
assay was performed to determine if the addition of d-
mannose would affect recognition of serum antibodies to
Fig. 4. (Panel A) Assessment of the anti-carbohydrate IgG reactivity in pooled mouse sera by ELISA. Serum reactivity was tested against Drosophila-made
WT YU2 gp120 (closed symbols) and deglycosylated gp120 antigens (open symbols). (Left panel) Sera raised against insect-made YU2 gp120-TH in Ribi
adjuvant tested against glycosylated and deglycosylated gp120 (open and closed triangles) and in Freund’s adjuvant (open and closed diamonds). (Right panel)
Prebleed negative control sera against glycosylated and deglycosylated gp120 (triangles) and serum raised against mammalian-made YU2 gp120 in Ribi
adjuvant (diamonds). (Inset) SDS-PAGE gel to confirm deglycosylation. Lane 1, Drosophila WTgp120; lane 2, deglycosylated gp120. (Panel B) d-mannose
inhibition ELISA. (Left panel) Binding of the monoclonal antibodies 2G12, IgGb12 (5 Ag/ml), and preimmune rabbit serum (Pb, 1:1000 serum dilution) to
Drosophila gp120 in the presence of increasing amounts of d-mannose. (Right panel) Binding of pooled rabbit sera raised against core+V3-TH gp120 (animals
1–5, 1:1000 serum dilution) to Drosophila WTgp120 in the presence of increasing amounts of d-mannose.
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effective blockade of mannose-reactive antibodies,
acknowledging the limitation that 2G12 binds only a
clustered subset of C4–V4 region glycans on the extensively
glycosylated gp120 (Sanders et al., 2002; Scanlan et al.,
2002; Trkola et al., 1996). In the assay, d-mannose
competed with 2G12 for binding to gp120 expressed in
Drosophila S2 cells in a dose-dependent manner (Fig. 4B).
At a concentration of 0.5 M d-mannose, 2G12-binding to
gp120 was completely inhibited. No d-mannose competi-
tion for binding of gp120 was observed with the negative
control CD4BS antibody IgG1b12 that recognizes gp120 in
a carbohydrate-independent manner. Binding of rabbit sera
raised against core+V3-TH gp120 and similarly, binding of
mice sera raised against WTgp120-TH, were only mini-
mally inhibited by d-mannose at the highest concentration
tested, suggesting low carbohydrate reactivity elicited by the
Drosophila high-mannose glycans on gp120 (Fig. 4B).
Data from both assays support the conclusion that no or
only slight additional carbohydrate reactivity was generatedby the addition of TH sequences. Presumably, the addition
of heterologous help did not break tolerance to glycan nor
elicit gp120-specific anti-carbohydrate antibodies to a
detectable level.
Effects of adjuvant on the immunogenicity of full-length
WTgp120 and WTgp120-TH produced in insect cells
To test if the observed differences in the ability of
WTgp120 and WTgp120-TH to elicit anti-gp120 IgG anti-
bodies were influenced by adjuvant, groups of five C57BL/6
mice were inoculated with 20 Ag of YU2 WTgp120 or YU2
WTgp120-TH emulsified in either Ribi adjuvant or Freund’s
adjuvant. The anti-gp120 IgG titers detected in sera raised
against WTgp120 and WTgp120-TH in Freund’s adjuvant
were higher than those raised by the same proteins emulsified
in Ribi adjuvant (Fig. 5). The endpoint titers in pooled sera
from the group inoculated with WTgp120-TH in Ribi
adjuvant were 1250 and 6250 after the second and third
inoculation, respectively. The titers raised with the same
Fig. 5. Effect of adjuvant on immunogenicity of gp120 and gp120-TH. Anti-gp120 IgG reactivity in pooled mouse sera raised against YU2 gp120 and YU2
gp120-TH immunogens was detected by ELISA after two (left panel) and three inoculations (right panel). Open and closed diamonds represent inoculations in
Ribi adjuvant, open and closed circles represent inoculations in Freund’s adjuvant.
Fig. 6. Effects of glycosylation on immunogenicity of gp120 and gp120-TH
immunogens. Anti-gp120 IgG reactivity in pooled sera from five animals
raised against YU2 gp120 and YU2 gp120-TH antigen was detected by
ELISA after three inoculations with mammalian-made gp120 in Ribi
adjuvant (closed triangles) and Drosophila-made gp120 and gp120-TH in
Ribi adjuvant (open and closed triangles) and Freund’s adjuvant (open and
closed circles).
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after two and three inoculations, respectively. The YU2
WTgp120 without TH elicited very low antibody titers after
two inoculations, the titers obtained with both adjuvants were
only slightly above the titers obtained with prebleed serum.
After three inoculations, however, the gp120 immunogen
raised significant antibody titers with Freund’s adjuvant, but
not with Ribi adjuvant. The endpoint titer of the pooled sera
raised against gp120 in Freund’s adjuvant after two inocu-
lations was 31,250 and 5-fold higher in pooled sera from the
WTgp120-TH group (Fig. 5).
Comparison of anti-gp120 IgG titers raised against
mammalian- and Drosophila-made full-length gp120
All core+V3 gp120 envelope glycoproteins used in the
above immunizations and ELISA assays were expressed in
Drosophila S2 cells. To determine the effect of the different
glycosylation patterns of mammalian and insect cells on the
immunogenicity of full-length gp120,WTgp120 expressed in
Drosophila S2 cells and in mammalian 293T cells was
inoculated into groups of C57BL/6 mice in Ribi adjuvant.
Anti-gp120 IgG titers were detected by ELISA after the third
inoculation (Fig. 6). The mammalian-made gp120 displayed
greater immunogenicity than both Drosophila-made gp120
and gp120-TH in Ribi adjuvant. The anti-gp120 reactivity
generated by Drosophila-made WTgp120-TH in Freund’s
adjuvant, however, was higher than that raised against
mammalian WTgp120 protein. As observed before, very
low reactivity was observed in sera raised against insect-made
WTgp120 in Ribi adjuvant. These results suggest that both
the source of the gp120 glycoprotein, which can influence the
carbohydrate structures on gp120, and the type of adjuvant
can influence the immunogenicity of the glycoprotein.Comparison of the anti-gp120 IgG titers elicited by native
gp120 relative to denatured gp120
The better IgG antibody responses elicited by the
Drosophila proteins when inoculated in Freund’s adjuvant
as compared to Ribi suggested that the state of denaturation
of gp120 might influence its immunogenicity. We had
already observed that native, YU2 WTgp120 elicited no
detectable IgG antibody response in Ribi adjuvant. There-
fore, we denatured both YU2 gp120 and YU2 gp120-TH by
boiling, reduction, and alkylation to test the effect of
treatment on the immunogenicity of proteins. By ELISA,
the denatured proteins were no longer recognized by either
C. Grundner et al. / Virology 330 (2004) 233–248 241CD4 or the conformationally sensitive CD4 binding site
antibody F105, but retained recognition by HIVIG at a level
comparable to native gp120 (data not shown). Interestingly,
as shown in Fig. 7, after two inoculations in Ribi adjuvant,
both denatured gp120 and denatured gp120-TH elicited
significantly higher IgG antibody titers specific for eitherFig. 7. The ELISA of anti-gp120 IgG elicited by native YU2 WTgp120-TH
(open squares), boiled-reduced-alkylated gp120 (closed circles), and boiled-
reduced-alkylated gp120-TH (closed squares) immunogens in Ribi adju-
vant. Preimmune sera are also shown (open triangles). In panel A, reactivity
to denatured, boiled-reduced-alkylated antigen is shown, in panel B,
reactivity to native gp120 is shown. The data are shown as the average of
five individual mice per immunogen group and the error bars represent
standard deviation. In panel C, the reactivity of pooled sera from each
immunogen group is shown against denatured, boiled-reduced but non-
alkylated gp120 antigen.denatured or native gp120 than did native WTgp120-TH as
an immunogen. We also analyzed the IgG response elicited
by the boiled-reduced-alkylated gp120 proteins directed
against boiled-reduced (denatured) but non-alkylated gp120
to confirm that the immune response was not directed
against neo-epitopes created by the alkylation process (Fig.
7). These data were obtained with the insect-derived
carbohydrate still present on the denatured protein, indicat-
ing that per se the carbohydrate does not dampen the T-cell-
dependent IgG response when present in the gp120
glycoprotein context.Discussion
Here, we present data that demonstrate a relatively poor
immunogenicity of HIV-1 core+V3 gp120 and full-length
gp120 derived from the primary isolate YU2 and expressed
in insect cells when tested in small animals. Table 2
summarizes the factors examined here that influence the
elicitation of a high-titer IgG response (or not) to the variant
gp120 glycoproteins. We interpret the inability of YU2
glycoproteins to efficiently elicit antibody responses to be
due to either lack of functional help or to inefficient
presentation to the CD4+ T-cell or B cell compartments.
The evidence for the lack of functional T-cell help is the
inability of mice and rabbits immunized with core+V3 and
full-length WTgp120 to class-switch from IgM to IgG
antibody production, a T-helper-cell-dependent process. A
possible explanation for the poor functional T-cell help may
be a general lack of T-helper cell epitopes in the gp120
envelope glycoprotein. Alternatively, cryptic T-cell helper
epitopes may be inefficiently utilized due to suboptimal
MHC class II processing and presentation. The latter
interpretation is supported by our observation that poorly
immunogenic YU2 WTgp120, when denatured, efficiently
elicited an anti-gp120 IgG antibody response. Regardless of
the precise mechanism, the observation that primary isolate
gp120 glycoproteins may possess suboptimal T-cell help is
relevant in regards to gp120-based subunit vaccine design,
as recently suggested by Zhan et al. (2003).
We initially studied this phenomenon in the context of
core+V3 gp120 envelope glycoproteins deleted of variable
loops V1 and V2, and parts of the C1 and C5 regions
(D82DV1/V2D492) designed to optimize the elicitation of
neutralizing antibodies. A number of studies have focused on
the identity and localization of T-helper epitopes in HIV-1
proteins (Clerici et al., 1989; Sitz et al., 1999; Surman et al.,
2001; Wahren et al., 1989). In a report of live-attenuated
SIV-derived Env that had been replicating in rhesus
macaques, gp120 exhibited a deficiency of helper epitopes
in most regions of the molecule with the exception of one
helper region detected in the C-terminal (C5) region of SIV
gp120 (Sarkar et al., 2002a, 2002b). For the primary clade B
isolate 1007 and the primary clade C isolate UG, three
hotspots of H2-IAb-restricted helper epitopes in HIV gp120
Table 2
Summary of factors contributing to high titer IgG response to the
immunogen determined by ELISAa






HX core + V3
gpl20
Ribi S2 Native Yes
HX core + V3-TH
gpl20d
Ribi S2 Native Yes
YU2 core + V3
gp120
Ribi S2 Native No
YU2 core + V3-TH
gp120
Ribi S2 Native Yes
YU2 WTgp120 Ribi S2 Native No
Freund’s S2 Native Yes
Ribi 293T Native Yes
Ribi S2 Denatured Yes
YU2 WTgpl20-TH Ribi S2 Native Yes
Freund’s S2 Native Yes
Ribi S2 Denatured Yes
a High titer IgG defined as an end point titer N1:30,000.
b S2 insect cells attach N-linked high mannose glycans whereas 293T cells
attach high mannose and complex glycans to gp120.
c Proteins are denatured by boiling, reduction, and alkylation.
d TH denotes heterologous helper epitope fusion peptides.
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same animal model used for portions of this study (Surman et
al., 2001). These hotspots locate to V2-C2, V3, and V4-C4,
with most of the epitopes found in C2 and V3 (22 of 26
total). If these data are interpreted in the context of the
core+V3 gp120 used here, deletion of the V1 and V2 loop in
these viral isolates would have removed only 2 of 26 helper
epitopes. Assuming that the distribution of helper epitopes
along hotspots is similar in other primary isolates, the
core+V3 gp120 molecules used here would not have been
rendered help deficient through deletion of the V1 and V2
loop alone. In both the SIV gp120 study (Sarkar et al., 2002a,
2002b) and the analysis of murine CD4+ responses to HIV
gp120 analysis (Surman et al., 2001), gp120 T-helper
epitopes were suggested to be limited by carbohydrate and
peptide exposure in the context of the three dimensional
structure of the protein. A number of T-helper epitopes
identified in this study do not appear to function in the
primary core+V3 gp120 molecules used in our study. The
differences between our results and the Surman study may be
accounted for by several factors. The immunization scheme
in the Surman study utilizes DNA or vaccinia virus priming
followed by protein boosting in Freund’s adjuvant, whereas
our study utilizes protein prime/boost in the less denaturing
Ribi adjuvant. Also, the in vitro stimulation of CD4+ T-cells
to map helper epitopes may not fully recapitulate the
functional in vivo presentation of a protein. This difference
in methodology also is true of the CD4+ T-helper epitope
analysis performed in rhesus macaques (Sarkar et al.,
2002b). In addition, the Surman study does not discriminate
helper responses of the TH1 and TH2 subtype, whereas the
antibody readout of our study is strongly biased toward
detecting T-helper responses of the TH2 type. A second studyby these investigators showed that the T-helper response in
C57BL/6 mice against a gp140 envelope glycoprotein was
extremely narrow (Zhan et al., 2003). The helper epitopes
identified in that study mapped almost exclusively to one
epitope on an exposed region of C2. The findings from both
of these studies suggest that the three-dimensional position-
ing of T-helper epitopes within native gp120 influences their
accessibility for antigenic processing.
Other studies have identified helper epitopes in the C1
region of gp120 deleted in the core+V3 glycoproteins (Dai
et al., 2001; Nehete et al., 1993, 1998); therefore, we
examined the effects of heterologous helper epitopes on full-
length gp120. We did not expect a total lack of immuno-
genicity of HIV-1 gp120 since numerous past studies have
reported that relatively high anti-gp120 titers can be elicited
using gp120 as an immunogen after several inoculations in
adjuvant (Barnett et al., 1997; Berman et al., 1990; Liao et
al., 2004; Ltd., 2003; Mascola et al., 1996; VanCott et al.,
1999). However, we wanted to determine if the addition of
TH sequences indicated that such proteins possessed
suboptimal T-cell help? In addition, we wanted to examine
the effects of the protein expression system since insect-
produced gp120 possesses only high-mannose carbohy-
drates whereas mammalian-expressed gp120 contains both
high mannose and complex glycosylation. Finally, we
assessed if the native structure of the heavily glycosylated
and cysteine-linked gp120 molecule would influence its
immunogenicity.
To explore whether heterologous helper epitopes would
also be beneficial in a full-length gp120 context, we tested
the immunogenicity of full-length YU2 gp120 with and
without TH in mice. As shown before for core+V3-gp120,
addition of the heterologous helper epitope TH also
enhanced the immunogenicity of full-length insect cell-
expressed gp120. The T-helper epitope deficiency of the
full-length molecule is particularly relevant for subunit
vaccine design in that it suggests that even if some T-helper
epitopes are provided by the immunogen, additional helper
epitopes may further increase the ability of gp120-based
vaccines to efficiently elicit a mature, T-cell-dependent
antibody response.
Since many of the early studies were performed using
Freund’s adjuvant, we wanted to also test the effect of
adjuvant on the immunogenicity of gp120. The gp120
emulsified in the relatively denaturing Freund’s adjuvant
elicits higher antibody titers than gp120 in Ribi adjuvant.
This effect might be explained by more efficient proteolytic
processing due to the denaturing effects of Freund’s on
gp120. In the partially denatured state, less accessible T-
helper epitopes normally buried inside the native protein
might become better exposed for class II processing and
presentation. Consistent with this interpretation, the dena-
tured gp120 and denatured gp120-TH examined here are
much more immunogenic than the native gp120 for the
elicitation of T-cell-dependent IgG responses (Fig. 7).
However, neither the nonphysiologic conditions of 50%
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protein denaturation, is likely to be desirable for the
elicitation of conformationally sensitive anti-gp120 neutral-
izing antibodies needed in a vaccine.
Differences in the glycosylation of gp120 expressed
from different cell types, in concert with adjuvant, also
clearly impacted on immunogenicity. When inoculated in
Ribi adjuvant, the native gp120 envelope glycoproteins
expressed in mammalian cells clearly elicited higher anti-
gp120 antibody titers than gp120 from insect cells. Only
Drosophila-made gp120-TH inoculated in Freund’s adju-
vant generated higher anti-gp120 titers than mammalian-
made gp120 in Ribi adjuvant. High-mannose carbohy-
drates of insect-made envelope glycoprotein may facilitate
faster clearance of the immunogen through the mannose
receptor and thus limit the availability of the immunogen
to B cells (Lee et al., 2002). However, presumably through
more efficient presentation to the class II pathway,
denaturation of gp120 overcame the effects of the high-
mannose carbohydrate to diminish the elicitation of an IgG
response.
The gp120 full-length or core+V3 glycoproteins used
here were selected in the context of human MHC alleles
whereas the T-helper epitope deficiency was observed in a
nonhuman background. However, we observed the same
helper epitope deficiency of primary isolate core+V3 gp120
in outbred animals, suggesting the intriguing possibility that
the reduced immunogenicity may have been influenced by
viral evolution away from efficient T-cell help in the context
of human host MHC. For this model to hold, gp120 would
have to be an immunogen separate from T-help provided by
other viral proteins. This could occur as a consequence of
the potentially labile gp120–gp41 interaction on infected
cells or virus. Shed, monomeric gp120 would be dissociated
from other viral proteins and could then be regarded as a
separate immunogen in vivo. In this study, we observed a T-
helper epitope deficiency in small animals. This would
imply that the general brulesQ regarding class II cleft
occupancy and T-cell recognition would have to be similar
cross-species for us to detect the effect on HIV gene product
evolution observed here. We would argue that this is a
reasonable suggestion since the very existence of PADRE
buniversal helper epitopesQ that function cross-species (see
Alexander et al., 1994 and results here) would imply that the
rules for occupancy of the class II cleft, and T cell
recognition, must follow some general trends of amino acid
biochemical character.
For a chronic virus such as HIV-1, virtually any means
that reduces viral immunogenicity will be of selective
advantage for the virus. Evolution away from T-cell help has
been previously reported for CD4 responses to LCMV
(Ciurea et al., 2001). One could envision that the survival of
the virus might be enhanced in vivo if denatured envelope
glycoproteins became immunodominant due to better
exposure of T-cell helper determinants. This would direct
the antibody response to denatured envelope glycoproteins,previously suggested to be a major immunogen in vivo
(Parren et al., 1997).
Suboptimal help elicited by primary isolate HIV-1
envelope glycoproteins has important implications for the
testing and design of subunit vaccines in both small animals
and potentially in human trials. It is becoming increasingly
clear that TCLA-derived envelope glycoproteins are not
optimal as subunit vaccines for the generation of neutraliz-
ing antibodies. Based upon our observations, however, the
use of primary isolate-derived envelope glycoproteins as
subunit vaccines may be complicated by the relative
deficiency in T-cell helper epitopes, at least at the initial
screening step almost always performed in small animals.
The addition of heterologous helper epitopes, as described
here, may be necessary to elicit titers high enough for
broadly neutralizing antibodies in these test animals. And
although the extrapolation from small animals to humans
should be done cautiously, a promiscuous heterologous
helper epitope such as PADRE (TH) might be highly
effective at consistently generating persistent, high-titer
circulating antibodies in a large human population possess-
ing an extensive diversity of MHC class II alleles.
Promiscuous heterologous help may deserve consideration
in future subunit vaccine trials that utilize immunogens
designed to improve upon the monomeric gp120 glycopro-
teins used in the recent Vaxgen clinical trial (Ltd., 2003). To
facilitate the elicitation of a recall response when the
vaccinated individual encounters challenge virus, however,
the use of additional homologous HIV-1-derived helper
epitopes would be warranted. The implications of these
results in the diverse human population are less clear as
factors such as improved adjuvants, repeated inoculations,
presentation of oligomeric forms of Env, and MHC diversity
may overcome some of the limitations on gp120 immuno-
genicity described here in small animals.Materials and methods
Envelope glycoprotein constructs
The core+V3 envelope glycoprotein constructs were
derived from the TCLA HIV-1 isolate HXBc2 and the
primary isolate YU2. The coding sequences of the envelope
glycoproteins were derived from the pSVIIIenv HXBc2 and
YU2 expression plasmids containing deletions of the V1 and
V2 variable loops as previously described (Wyatt et al.,
1995). Briefly, the V1–V2 coding region was deleted from
amino acids 128–194 and replaced with a Gly-Ala-Gly
sequence. The amino acid numbering is based on the
prototypic HIV-1 HXBc2 strain according to current con-
vention (Korber et al., 1998). Subcloning of sequences
encoding these core+V3 glycoproteins into the insect
expression vector pMT (Culp et al., 1991) containing the
inducible metallothionein promoter (MT) and tissue plasmi-
nogen leader (tPA) sequence was performed as follows. The
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the N- and C-terminal sequences (D82 and D492) and to
append a 5VBamHI and a 3VXbaI site. The PCR products
were digested with BamHI and XbaI. The pMT expression
plasmid was digested with BglII and NheI to obtain
compatible overhangs. The insert was then ligated into the
pMT expression plasmid. For the generation of gp120
core+V3 constructs containing 5V and 3V TH sequences
(amino acid sequence AKFVAAWTLKAAA; Alexander et
al., 1994), the TH as well as BamHI and XbaI sites were
appended by PCR to the core+V3-coding sequence in the
pMT expression plasmid. The PCR products were purified,
digested with BamHI and XbaI, and inserted into the pMT
vector cut with BglII and NheI. The following primers were
used for PCR amplification. YU2 forward: 5V-TTT GCG
GCC GCG GAT CCG CGT TCG TGG CGG CGT GGA
CGT TGA AGG CGG CGG CCG AAG TAA AAT TGG
AAA ATG TGA CAG-3V. YU2 reverse: 5V-TTT TGT TCT
AGATCACCCCCCCCCCGCCTT TAAAGTCCACGC
CGC CAC GAA CGC TTC AAT TTT TAC TAC TTTATA
TTT-3V. HXBc2 forward: 5V-TTT GCG GCC GCG GAT
CCG CGT TCG TGG CGG CGT GGA CGC TTA AGG
CGG CGG CGG AAG TAA AAT TGG AAA ATG TGA
CAG-3V. HXBc2 reverse: 5V-TTT TGT TCTAGATCA CCC
CCC CCC CGC CTT AAG CGT CCA CGC CGC CAC
GAA CGC TTC AAT TTT TAC TAC TTTATATTT-3V. The
presence of the in-frame sequences encoding the THmoieties
was confirmed by DNA sequencing and N-terminal sequenc-
ing (data not shown; note, the use of the tPA leader in insect
cells results in the addition of four N-terminal residues, G-A-
R-S, before the TH sequence).
The coding sequence of the YU2 full-length gp120
envelope glycoprotein was derived from a codon-optimized
YU2 gp140 expression plasmid (kindly provided by M.
Farzan) in the pcDNA3.1- vector (Invitrogen). Subcloning
of the full-length gp120 into the insect expression vector
pMT was performed as described above for core+V3 gp120
using primers specific for the full-length gp120. The
PADRE sequences were appended at the 3Vand 5Vends of
full-length gp120 by PCR using the following primers. YU2
forward: 5V-TTT TGT TTT GGA TCC GCG AAG TTC
GTG GCG GCG TGG ACG CTT AAG GCG GCG GCG
GTG GAG AAG CTG TGG GTG ACT GTA-3. YU2
reverse: 5V-TTT TGT TTT TCTAGATCA CGC CGC CGC
CTT AAG CGT CCA CGC CGC CAC GAA CTT CGC
GCT CTT CTC GCT CTG CAC CAC-3V. The presence of
the PADRE sequences was confirmed by DNA sequencing
of the expressor plasmid and N-terminal sequencing of the
protein.
Production of recombinant envelope glycoprotein in
Drosophila S2 cells
Drosophila S2 cells were transfected by the Ca3(PO4)2
method using a 20:1 ratio of the pMT vector expressing the
envelope glycoprotein and the pCohygro plasmid, whichconfers hygromycin B-resistance. Following transfection,
S2 cells were washed and maintained in MRD4 medium
supplemented with 5% heat-inactivated fetal calf serum
(HIFCS) and 0.1% pluronic F-68 (Sigma) at 25 8C. After 48
h, hygromycin B (Boehringer Mannheim) was added to a
final concentration of 300 Ag/ml. When growth was
observed in cultures 3–4 weeks after transfection, the
cultures were expanded and incubated in shaking flasks at
25 8C. The cells were expanded and induced to produce
recombinant envelope glycoproteins by pelleting the cells at
300  g and resuspending them in serum-free induction
medium (MRD4 with 750 AM CuSO4 and 0.1% pluronic F-
68). The cells were then incubated at 25 8C with shaking for
5–7 days. The cell supernatant was collected and filtered
through a 0.45-Am filter system (Corning). The supernatant
was passed over an F105 antibody affinity column prepared
from F105 antibody covalently linked to protein A-
sepharose (Amersham Biosciences). The column was
washed with 10 column volumes of phosphate-buffered
saline (PBS) containing 0.5 M NaCl, followed by 10
column volumes of PBS. Bound protein was eluted with 5
ml of 100 mM glycine–HCl pH 2.3 and the eluate was
neutralized by adding 2 M Tris base. The eluate was then
concentrated using a Centriprep YM-30 concentrator
(Millipore). The protein concentration of the preparation
was determined photometrically by determining the absorp-
tion at 280 nm using extinction coefficients determined for
each envelope glycoprotein construct from the primary
amino acid sequence.
Deglycosylation of YU2 core+V3 gp120 and WTgp120
For the enzymatic deglycosylation of Drosophila-pro-
duced gp120, the proteins (0.5 mg/ml) were incubated with
0.1 unit/ml of endoglycosydase D and 0.25 units/ml
endoglycosidase H (Roche) in 0.5 M NaCl, 100 mM sodium
acetate buffer, pH 5.7 for 10 h at 37 8C. The deglycosylation
of gp120 was confirmed by SDS-PAGE as a reduction in
molecular weight relative to WT gp120 protein (Fig. 5A).
ELISA
High protein-binding microtiter plates (Corning) were
coated with 100–200 ng/well of affinity-purified envelope
glycoprotein produced in Drosophila S2 cells in 100 Al of
PBS overnight at 4 8C. The plates were washed once in
washing buffer (PBS containing 0.2% Tween 20) and
blocked with blocking buffer (PBS containing 2% (w/v)
nonfat dried milk and 5% FCS) for 1 h at room temperature
(RT). Serum was serially diluted in 100-Al final volume per
well in blocking buffer and incubated for 2 h at RT. After
two washes with PBS 0.2% Tween 20, the wells were
incubated with 100 Al of washing buffer containing
secondary antibody. For the analysis of mouse serum for
IgG reactivity to gp120, a 1:2000 dilution of anti-mouse-
IgG-biotin antibody (Sigma) in washing buffer was added
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with streptavidin-horseradish peroxidase (HRP) at a 1:4000
dilution for 30 min. For the detection of mouse IgG in Fig.
14, an anti-mouse IgG-HRP antibody conjugate (Sigma)
was used at a 1:10,000 dilution for 1 h at RT.
For the analysis of rabbit sera, a secondary anti-rabbit-
IgG-HRP antibody (Sigma) was added in washing buffer at
a 1:2000 dilution for 1 h at RT. For the detection of IgM in
rabbit serum, an anti-rabbit-IgM-HRP antibody (Sigma) was
used at a 1:2000 dilution. Following three washes, the
ELISAs were developed with TMB Peroxidase substrate
(KPL). Endpoint titers were defined as last reciprocal serum
dilution at which the absorption at 450 nm was greater than
2-fold over the signal detected with preimmune serum.
For the detection of IgG1 and IgG2a subclass antibodies,
ELISA plates were coated with gp120 as described above.
The plates were incubated with serial dilutions of serum,
and IgG1 and IgG2a antibodies were detected using HRP-
conjugated goat anti-mouse IgG1-specific secondary anti-
body (SouthernBiotech) at a 1:5000 dilution and a goat anti-
mouse IgG2a-specific HRP-conjugated secondary antibody
(SouthernBiotech) at a 1:5000 dilution. As a positive
control, purified mouse IgG2a kappa and purified mouse
IgG1 kappa antibodies (Sigma) were coated on the plate at a
starting dilution of 1 Ag/well (10 Ag/ml) and serially diluted
10-fold. Immune serum was omitted from positive control
IgG2a and IgG1 protein wells. The control wells were
incubated with the same IgG1- and IgG2a-specific secondary
antibodies as the wells incubated with the anti-gp120
immune serum.
Splenocyte preparation
All cells and solutions were kept on ice at 4 8C. All
centrifugation was performed for 10 min, 4 8C at 300  g.
Mice spleens were forced through a 70-Am nylon filter
(Thomas Scientific) with the rubber head of 3-ml syringe.
The filter was then washed with 5–10 ml of RPMI 1640
medium containing 2 mM l-glutamine, 25 mM HEPES, 1%
nonessential amino acids, 1% sodium pyruvate, 0.1% beta-
mercaptoethanol, 1% penicillin-streptomycin, and 10%
FCS. The samples were centrifuged to pellet the cells and
the supernatants were discarded. The cell pellets were
resuspended in 1 ml of ACK lysing buffer (Biofluids) and
incubated on ice for 8 min to lyse the red blood cells. Nine
milliliters of RPMI medium was added and the cells were
pelleted, resuspended in medium, and then subjected to two
more cycles of resuspension and centrifugation. The final
cell pellet was resuspended in 1–10 ml of RPMI medium
and the cells were counted to obtain the final concentration
of 2  106 cells/ml.
Mouse IL-4 ELISPOT
Anti-mouse IL-4 antibody (100 Al at 1:200 dilution in
sterile PBS, pH 7.2) was added to each well of an ELISPOTplate (BD Biosciences) and stored at 4 8C overnight. The
plates were then washed once with 200 Al/well of blocking
solution (RPMI 1640 containing l-glutamine, 10% FCS,
1% penicillin-streptomycin). The plates were blocked for 2
h at RT with PBS containing 2% nonfat dry milk and 5%
HIFCS. Following blocking, 0.1 and 1 Ag/well of affinity
purified gp120 or gp120-PADRE in blocking solution were
added to the ELISPOT plate in a 100-Al volume. The cell
suspension was prepared at 2  106/ml and 100 Al/well was
added to the plate. The ELISPOT plate was incubated at 37
8C in a 5% CO2 humidified incubator for 24 h. After 24 h,
the cell suspensions were discarded. The wells were washed
twice with milliQ water and then three additional times with
PBS containing 0.05% Tween 20. Next, biotinylated anti-
mouse IL-4 (1:250 dilution in PBS, 10% FCS) was added to
the plate and incubated for 2 h at RT. All wells were washed
three times with PBS, 0.05% Tween 20. Avidin-horseradish
peroxidase (100 Al/well at a 1:100 dilution in PBS
containing 10% FCS) was added to the plate and incubated
for 1 h at RT. The wells were washed four times with PBS
0.05% Tween 20 followed with two PBS washes. Next, 100
Al of substrate solution was added to each well as per
manufactures recommendation (one tablet of AEC (Sigma)
was added to 2.5 ml dimethylformamid). In parallel, acetate
buffer was prepared as follows: 46.9 ml milliQ water, 4.6 ml
0.1 N acetic acid, 11 ml 0.1 M sodium acetate. 47.5 ml of
acetate buffer was added to the soluble AEC solution.
Finally, 25 Al of 30% H2O2 was added and the solution was
filtered through a 0.45-Am filter. Spot development was
monitored for 15 min. The substrate conversion reaction
was stopped by washing wells with milliQ water. The plates
were air-dried at RT overnight and the plates were stored in
the dark. The spots were counted using Axioplan 2 Imaging
from Carl Zeiss Inc.
Denaturation of the YU2 gp120 and gp120-TH proteins and
ELISA analysis
Denaturation of the gp120 proteins was accomplished by
boiling for 10 min at 100 8C followed by reduction with 100
mM DTT at 37 8C for 30 min. The proteins were then
dialyzed against PBS. For irreversible denaturation, some
proteins were alkylated by the addition of 20 mM of
iodoacetamide at 37 8C for 1 h. The boiled-reduced-
alkylated proteins were then dialyzed against PBS. SDS
gels PAGE and ELISA with CD4, F105, and HIVIG were
performed to confirm recovery of the denatured proteins as
previously described: either native or denatured gp120 was
coated on the plate overnight. Subsequently, an ELISA was
performed comparing the reactivity of native gp120 to
boiled-reduced gp120 or boiled-reduced-alkylated with the
conformation-sensitive ligands CD4 and F105 antibody and
the less conformation-dependent HIV-pooled patient IgG
(HIVIG). No recognition of the denatured proteins above
background levels could be observed with CD4 and F105
while HIVIG recognition was retained.
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Female, 4- to 6-week-old mice were purchased from
Taconic laboratories. Groups of six C57BL/6 and BALB/c
mice were inoculated subcutaneously with 20 Ag of gp120
resuspended in 200 Al of MPL + TDM Ribi adjuvant
(Sigma) or complete Freund’s adjuvant (Sigma). The
inoculation was repeated four times in 4-week intervals in
incomplete adjuvant for the Freund’s inoculated animals.
Eyebleeds (tailbleeds for full-length gp120) were performed
7 days after each inoculation. Blood was collected and
incubated at 4 8C overnight to allow clot formation. Serum
was collected after pelleting the clot by spinning for 10 min
at 14,000 rpm in an Eppendorf microtube centrifuge.
For the immunization of rabbits, groups of five New
Zealand White rabbits were inoculated intradermally with 1
ml of antigen solution containing 20 Ag of envelope
glycoprotein emulsified in MPL + TDM + CWS Ribi
adjuvant (Sigma). Inoculations were administered 4, 8, and
12 weeks after the initial inoculation. Earbleeds were
performed 7–14 days after each inoculation except the first.
The blood samples were incubated overnight at 4 8C in a
Vacutainer SST Gel Clot Activator (Becton Dickinson) and
spun for 30 min at 1500  g at 4 8C. The cleared serum was
stored at 20 8C.Acknowledgments
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